Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Foghorn Therapeutics Inc.

Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Our proprietary Gene Traffic Control® platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within the system.

Flagship Pioneering

Casdin Capital

Invus

Irving Investors

Happy New Year from all of us at Foghorn! As we kick off 2024, we look forward to the year ahead as we continue to advance our mission to transform patient’s lives by correcting abnormal gene expression. #biotechnology #innovation #oncology

Check out photos of our Foghorn team, who had fun swapping surprises at our end of year holiday party. From all of us at Foghorn, wishing everyone a healthy and happy holiday season! #HappyHolidays

That's a wrap on the 65th Annual American Society of Hematology Meeting! Our team enjoyed coming together with the scientific community to present data and talk about our novel approach to modulating the chromatin regulatory system. Read all of our recent data presentations from #ASH23 and beyond: https://bit.ly/3GJ2vkZ

Martin (Murphy) Hentemann Kathleen Healy Caroline Almon #biotechnology #innovation #TPD

Meet Alexia Kalogeropulou, one of our brilliant scientists at Foghorn. Alexia shares why she loves the collaborative culture that enables us to advance our mission to transform the lives of people living with a wide spectrum of diseases. #LifeAtFoghorn #WomenInSTEM #biotechnology

Join us at the 2nd Annual TPD Assay Development & Screening Summit, where our Head of #DrugDiscovery, Marina Nelen, will be part of a panel to discuss high-throughput screening approaches and applications of assay techniques to degrader triage and profiling. See the agenda: https://ow.ly/J9Bh50QfwVc
#biotechnology #innovation #proteindegradation

We’re looking forward to the 65th American Society of Hematology Annual Meeting and Exposition, where clinical data from the Phase 1 dose-escalation study of FHD-286 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) will be presented. Learn more: https://ow.ly/wc3q50Qel4h
#ASH23

We know that our people are the key to our success, which is why we embrace a people first culture. Our culture is just one reason that Madeleine Henley was drawn to Foghorn. Learn more about our culture: https://ow.ly/Ca4050Qe2u8 

#LifeAtFoghorn #WomenInSTEM

Happy #Thanksgiving to all! Today, we are especially thankful for the incredible Foghorn team and their unwavering commitment to our mission of transforming lives across a wide spectrum of diseases. #biotechnology #innovation

Last week, we had the pleasure of joining other leading experts in the chromatin and epigenetics field during #Epi2023, where Dave Lahr gave a presentation on our preclinical work during a session on the nucleosome and chromatin remodeling. Find all our recent data presentations here: https://lnkd.in/gUtu9Wfi

#biotechnology #oncology #innovation

Congratulations to this year's recipients of the 2023 Paul Marks Prize for Cancer Research, including our scientific co-founder, Cigall Kadoch! This award underscores the important work being done at Foghorn to address breakdowns in the chromatin regulatory targets to advance novel treatments in cancer and beyond. #oncology #cancerresearch #innovation

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
average inventory
average payables		2.73M -	3.56M 30.55%	3.75M 5.34%	4.62M 23.12%	5.84M 26.44%
average receivables				150M -	150M 0%
book value per share	-2.00 -	-3.98 98.81%	13.23 432.69%	2.61 80.31%	0.00 99.90%	-0.00 168.29%
capex per share	-0.08 -	-0.04 44.27%	-1.46 3,248.71%	-0.09 93.92%	-0.03 67.36%	-0.00 99.90%
capex to depreciation	-4.07 -	-1.40 65.65%	-12.20 773.06%	-1.03 91.58%	-0.36 64.51%	-0.35 2.65%
capex to operating cash flow	0.07 -	0.02 69.30%	0.52 2,375.96%	0.07 87.25%	-0.01 109.48%	0.01 265.83%
capex to revenue			-37.63 -	-2.51 93.33%	-0.06 97.49%	-0.04 43.05%
cash per share	2.04 -	0.68 66.79%	16.82 2,383.87%	4.15 75.32%	15.37 270.36%	0.01 99.96%
days of inventory on hand
days payables outstanding					102.77K -
days sales outstanding				83.02K -
debt to assets	0.16 -	0.74 355.94%	0.32 56.90%	0.11 65.02%	0.13 13.36%	0.16 23.92%
debt to equity	-0.18 -	-0.19 5.56%	0.56 396.88%	0.60 7.36%	459.88 76,272.17%	-0.58 100.13%
dividend yield
earnings yield	-0.07 -	-0.13 74.03%	-0.31 141.82%	-0.12 61.03%	-0.41 237.89%	-0.00 99.91%
enterprise value	322.70M -	402.60M 24.76%	213.12M 47.06%	807.30M 278.80%	-28.94M 103.58%	270.70B 935,559.82%
enterprise value over ebitda	-12.63 -	-8.07 36.10%	-3.22 60.10%	-8.50 164.10%	0.25 102.91%	-2.51K 1,015,585.30%
ev to operating cash flow	-14.25 -	-8.69 39.02%	-6.81 21.60%	-16.07 135.84%	-0.15 99.07%	-2.29K 1,533,405.89%
ev to sales			495.63 -	612.05 23.49%	-1.50 100.25%	7.93K 526,729.23%
free cash flow per share	-1.23 -	-2.14 73.48%	-4.30 101.01%	-1.44 66.47%	4.63 421.03%	-0.00 100.06%
free cash flow yield	-0.07 -	-0.12 73.48%	-0.21 79.69%	-0.06 70.28%	0.73 1,250.78%	-0.00 100.06%
graham net net	-2.16 -	-4.31 99.97%	6.91 260.37%	-1.17 116.97%	5.64 580.76%	-0.00 100.05%
graham number	7.77 -	14.46 86.01%	43.37 200.00%	12.76 70.58%	0.40 96.88%	0.01 97.53%
income quality	0.86 -	0.91 5.39%	0.45 49.82%	0.50 9.06%	-1.78 458.54%	1.20 167.48%
intangibles to total assets	0 -	0	0	0	0	0
interest coverage	-70.21 -	-94.60 34.73%	-70.00 26.00%	-52.85 24.50%	10.13 119.16%
interest debt per share	0.38 -	0.78 105.82%	7.51 868.05%	1.62 78.42%	0.96 40.74%	0.00 99.89%
inventory turnover
invested capital	-0.18 -	-0.19 5.56%	0.56 396.88%	0.60 7.36%	459.88 76,272.17%	-0.58 100.13%
market cap	355.69M -	400.95M 12.73%	223.92M 44.15%	850.10M 279.65%	265.35M 68.79%	270.74B 101,928.27%
net current asset value	-41.93M -	-93.47M 122.93%	81.28M 186.96%	36.66M 54.90%	-58.97M 260.87%	-122.92M 108.44%
net debt to ebitda	1.29 -	-0.03 102.56%	0.16 593.87%	0.45 176.35%	2.51 457.33%	0.33 86.99%
net income per share	-1.34 -	-2.34 74.03%	-6.32 170.52%	-2.78 56.04%	-2.62 5.74%	-0.00 99.91%
operating cash flow per share	-1.15 -	-2.09 81.49%	-2.83 35.25%	-1.35 52.27%	4.66 444.35%	-0.00 100.06%
payables turnover					0.00 -
receivables turnover				0.00 -
research and ddevelopement to revenue			134.22 -	60.90 54.63%	5.49 90.98%	3.21 41.53%
return on tangible assets	-0.61 -	-2.31 278.08%	-0.27 88.19%	-0.20 27.26%	-0.27 35.40%	-0.34 28.02%
revenue per share			0.04 -	0.04 8.84%	0.46 1,202.84%	0.00 99.82%
roe	0.67 -	0.59 12.46%	-0.48 181.31%	-1.07 123.24%	-972.09 91,124.15%	1.28 100.13%
roic	0.81 -	0.74 8.83%	-0.24 132.38%	-0.48 100.89%	-1.14 136.32%	-7.96 600.40%
sales general and administrative to revenue			26.15 -	16.47 37.01%	1.60 90.29%	0.95 40.73%
shareholders equity per share	-2.00 -	-3.98 98.81%	13.23 432.69%	2.61 80.31%	0.00 99.90%	-0.00 168.29%
stock based compensation to revenue			6.89 -	6.36 7.69%	0.75 88.27%	0.47 36.44%
tangible asset value	-39.27M -	-88.02M 124.11%	146.19M 266.09%	96.87M 33.73%	112K 99.88%	-77.19M 69,019.64%
tangible book value per share	-2.00 -	-3.98 98.81%	13.23 432.69%	2.61 80.31%	0.00 99.90%	-0.00 168.29%
working capital	36.94M -	4.23M 88.54%	171.84M 3,959.56%	410.87M 139.10%	8.98M 97.81%	181.75M 1,924.34%

NASDAQ:FHTX

Foghorn Therapeutics Inc.

Last Close

5.81

17/05 20:00

Market Cap

128.76M

Beta: 2.16

Volume Today

59.69K

Avg: 76.72K

PE Ratio

−1.07

PFCF: −0.97